Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Prosthesis-patient mismatch after TAVR makes minimal impact on long-term outcomes

Researchers tracked SWEDEHEART data from more than 8,000 TAVR patients treated from 2008 to 2022. Overall, they said, PPM after TAVR was rare, and its impact on outcomes was "negligible."

Magenta Medical, an Israeli healthcare technology company, has closed a funding round worth $105 million.

Medical device company raises another $105M for new-look heart pump

Magenta Medical plans to use some of the new financing to secure FDA approval for its Elevate LVAD. Novo Holdings, the controlling shareholder of international healthcare company Novo Nordisk, led the funding round.

suzanne_baron_md.png

Q&A: Interventional cardiologist breaks down SMART data and TAVR valve performance in patients with small annuli

Sponsored by Medtronic

Some of the most talked about data at ACC.24 were the results of a late-breaking clinical trial comparing different transcatheter aortic valve replacement (TAVR) valves in patients with a small aortic annulus. 

doctor's open hand waiting for a payment

Changing with the times: How interventional cardiology finally met its Match

Trainees interested in interventional cardiology will now be able to use the Match program to find the right program for their needs. The move is associated with multiple benefits as well as some key challenges.

Newsweek ranked the 50 best heart hospitals in the world

Leadless vs. transvenous pacemakers after TAVR: Tracking complications, costs and survival

Leadless pacemakers may be an "attractive alternative" to transvenous devices when cardiologists treat older TAVR patients who experience conduction disorders.

Cordis has received U.S. Food and Drug Administration (FDA) approval for its new MYNX Control Venous Vascular Closure Device (VCD) for 6F-12F access sites. The company hopes to launch the newly approved extravascular closure device in the months ahead.

Cordis gains FDA approval for new closure device, inks pricing deal with Premier

The newly approved extravascular closure device was designed for procedures with access sites from 6 to 12 French. It uses the same proprietary GRIP technology found in other Cordis interventional devices.

StreamlineValve self-cleaning TAVR valve inspired by nature

Self-cleaning TAVR valve offers potential of fewer clots, better outcomes

Inspired by nature and funded by the European Research Council, a group of scientists and engineers thinks its new research could represent a significant breakthrough in TAVR care.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Temporary pacemakers after TAVR could reduce need for permanent implants

Care teams are always looking for new ways to limit the use of permanent pacemakers after TAVR. Could starting patients off with temporary devices be an answer? 

Displaying 113 - 120 of 973
Design by Adaptive Theme